Clinical Trials
427 trialsA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
NeoB-Cap1
Novartis
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
FRAmework-01
Eli Lilly and Company
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
Ottawa Hospital Research Institute
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
M.D. Anderson Cancer Center
CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
Zhejiang University
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
University of Washington
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Thomas Jefferson University
AHEAD-MERIT
BioNTech SE
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Oncorena AB
MCW I-PREDICT
Medical College of Wisconsin
Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
Hackensack Meridian Health
NEXUS-01
Eli Lilly and Company
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeOne Medicines
OMNIRAY
Eli Lilly and Company
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
FORAGER-2
Eli Lilly and Company
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
INDIGO
Boston Scientific Corporation
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
FORAGER-1
Eli Lilly and Company
SUNRAY-01
Eli Lilly and Company
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
VISTA-1
Riboscience, LLC.
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Keynote B59
GI Innovation, Inc.
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
IDeate-Prostate02
Merck Sharp & Dohme LLC
MAPKeeper 301
Immuneering Corporation
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Exelixis
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Arsenal Biosciences, Inc.
OP-NEU-101
Onchilles Pharma Inc
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)